Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Lindsey E. Roeker,Tatyana A. Feldman,Jacob D. Soumerai,Victoria Falco,Gail Panton,Colleen Dorsey,Andrew D. Zelenetz,Lorenzo Falchi,Jae H. Park,David J. Straus,Camila Pena Velasquez,Sonia Lebowitz,Yehudit Fox,Kristen Battiato,Carissa Laudati,Meghan C. Thompson,Elizabeth McCarthy,Sabrina Kdiry,Rosalba Martignetti,Teja Turpuseema,Michelle Purdom,Dana Paskalis,Hari P. Miskin,Peter Sportelli,Lori A. Leslie,Anthony R. Mato crossref（2023）
摘要
Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
更多查看译文
AI 理解论文
溯源树
样例
